A patient's face with one side drifting into purple blood cells representing a hematologic neoplasmA patient's face with one side drifting into purple blood cells representing a hematologic neoplasm
Why it is
To talk about…
CD123 and
~85% to 90% of patients with BPDCN present with skin lesions1-3
Purple skin lesions caused by BPDCN
 Dermatologists may be the first to recognize the signs of BPDCN and biopsy unusual or treatment-resistant lesions4-6
Follow the
dermatologists’ path
The CD123 marker is highly expressed (~95%) on BPDCN cells1,5,7
A graphic showing that BPDCN testing should include CD123, in combination with CD4 and CD56
Pathologists can test for BPDCN by including CD123, in combination with CD4 and CD56, in every hematologic diagnostic panel4,8*
Follow the
pathologists’ path
BPDCN is a rare and clinically aggressive hematologic malignancy with poor outcomes7,9,10
Stylized BPDCN cells colored purple
Hematologist-Oncologists can push for an early diagnosis of BPDCN to help improve its poor outcomes and provide appropriate treatment4,10
Follow the hemato-oncologists’ path
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Early diagnosis of this deadly cancer is critical and may take a multidisciplinary team4
* The diagnosis of BPDCN requires immunophenotyping and fundamentally relies on the demonstration of CD4, CD56, CD123, CD303, and TCL1 expression, together with a lack of expression of markers for B cells, T cells, myeloid or monocytic cells, and NK cells.4,5
BPDCN = blastic plasmacytoid dendritic cell neoplasm;
CD = cluster of differentiation;
NK = natural killer;
TCL1 = T-cell leukemia/lymphoma protein 1A.
  1. References:
  2. 1. Laribi K, et al. Biol Blood Marrow Transplant. 2016;22(8):1357-1367.
  3. 2. Sullivan JM, Rizzieri DA. Hematology Am Soc Hematol Educ Program. 2016(1):16-23.
  4. 3. Julia F, et al. Br J Dermatol. 2013;169(3):579-586.
  5. 4. Pagano L, et al. Br J Haematol. 2016;174(2):188-202.
  6. 5. Facchetti F, et al. Mod Pathol. 2016;29(2):98-111.
  7. 6. Shapiro R, et al. J Cell Sci Ther. 2015;S8:008.doi:10.4172/2157-7013.S8-008.
  8. 7. Pagano L, et al. Haematologica. 2013;98(2):239-246.
  9. 8. Pemmaraju N, Konopleva M. Blood Adv. 2020 Aug 25;4(16):4020-4027.
  10. 9. Laribi K, et al. Blood Adv. 2020 Oct 13;4(19):4838-4848.
  11. 10. Deconinck E, et al. 2021 Fast Facts© S. Karger Publishers Ltd.